Gyros this week announced a partnership with EMD Millipore to develop, manufacture, and commercialize immunoassay kits for the Gyrolab platform.

The new kits will take advantage of the capabilities of Gyros' microfluidic technology, which, according to the company, requires smaller sample and reagent volumes and offers increased dynamic range and reduced cross-talk and matrix interference compared to traditional ELISAs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.